Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

Pursue advocacy efforts We’ve seen critical legal decisions over the last five years either accelerate or stymie the United States biosimilar market. In the 2017 Amgen v. Sandoz case, the ...

PT: How does pharma deal with diverse geographies during launch? AH: This is difficult! Local and national reimbursement environments vary significantly by country and many will reference ...

Drug development is a high-stakes, high-cost endeavour. Every new drug entering clinical trials requires careful decision-making, particularly regarding trial design and resource allocation.

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

As we commence 2025, for those who are considered leaders or visionaries in their fields, it’s time to dust off the crystal ball and make some bold predictions about what this year will bring.

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.